Does Cosentyx Trigger Allergic Reactions?
Yes, Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lists allergic reactions among its potential side effects. The prescribing information notes hypersensitivity reactions, including angioedema (swelling under the skin), rash, urticaria (hives), and in rare cases anaphylaxis. These can occur after injection or infusion and may happen even after prior doses.[1]
How Common Are They and What Symptoms to Watch For?
Allergic reactions affect less than 1% of patients in clinical trials, but post-marketing reports highlight risks like:
- Itching, redness, or pain at the injection site (common, up to 15% of users).
- Systemic signs: difficulty breathing, swelling of face/lips/tongue/throat, rapid heartbeat, dizziness, or widespread rash.
Severe cases require immediate medical attention; mild ones may resolve by pausing treatment.[1][2]
What Increases the Risk?
Patients with a history of allergies, asthma, or prior biologic exposure face higher odds. Auto-injector use can cause local reactions mistaken for allergies. No specific genetic markers predict risk, but monitoring is standard during the first doses.[1]
How Do Doctors Handle Reactions?
Treatment follows standard protocols: stop Cosentyx, administer antihistamines or epinephrine for anaphylaxis, and consider alternatives like dupilumab. Skin testing isn't routine due to lack of validated methods. Re-challenge is rare and only under supervision.[1][2]
Compared to Similar Drugs
Cosentyx's allergy rate aligns with other IL-17 blockers like Taltz (ixekizumab), where hypersensitivity hits 1-2%. TNF inhibitors (e.g., Humira) report similar frequencies, but monoclonal antibodies overall carry a 0.5-2% anaphylaxis risk across classes.[2]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Adverse Event Reporting System (FAERS) data via Drugs.com